Ad5SARS-CoV-2BALB/c

Tongyao Mao1, Peng Zhang1, Surui Jiang1,2

  • 1National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases (NITFID), NHC Key Laboratory for Medical Virology and Viral Diseases, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.

Journal of medical virology
|February 14, 2025
PubMed
概括

一种针对SARS-CoV-2的新型口服疫苗Omicron BA.1在小鼠中表现出强大的粘膜和全身免疫力. 这种腺病毒疫苗提供了一种有前途的策略,可以克服针对新兴病毒变异的现有疫苗的局限性.